Cross-Disease Therapeutic Targets in 4R-Tauopathies

📖 Wiki Page

therapeutic1704 wordssynced 2026-04-02

Cross-Disease Therapeutic Targets in 4R-Tauopathies

Overview

...

Cross-Disease Therapeutic Targets in 4R-Tauopathies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cross-Disease Therapeutic Targets in 4R-Tauopathies</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Abbreviation</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>CBD</td>
</tr>
<tr>
<td class="label">Argyrophilic Grain Disease</td>
<td>AGD</td>
</tr>
<tr>
<td class="label">Globular Glial Tauopathy</td>
<td>GGT</td>
</tr>
<tr>
<td class="label">FTDP-17</td>
<td>FTDP-17</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Methylthioninium chloride (MTC)</td>
<td>Tau aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>GSK-3β inhibitor, reduces tau phosphorylation</td>
</tr>
<tr>
<td class="label">Davunetide (AL-108)</td>
<td>Tau phosphorylation inhibitor</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate</td>
<td>Tau acetylation modulator</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Pexidartinib, BLZ945 for microglia depletion</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Anti-TREM2 antibodies</td>
</tr>
<tr>
<td class="label">CD22</td>
<td>Antibody blockade</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR inhibition</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>TFEB activation, mTOR-independent autophagy</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Autophagy induction</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>Mitophagy enhancement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau aggregation</td>
<td>Methylthioninium</td>
</tr>
<tr>
<td class="label">Tau-Specific immunotherapy</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">Tau kinase inhibition</td>
<td>Tideglusib, lithium</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>CoQ10, IGF-1</td>
</tr>
<tr>
<td class="label">Oculomotor function</td>
<td>3,4-Diaminopyridine</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau immunotherapy</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">Antibody-based</td>
<td>Anti-tau oligomer</td>
</tr>
<tr>
<td class="label">TREM2 modulation</td>
<td>Anti-TREM2 antibodies</td>
</tr>
<tr>
<td class="label">Synaptic protection</td>
<td>Levetiracetam</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau acetylation</td>
<td>Salsalate, tributyrin</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>Tau + neuroinflammation</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Oligodendrocyte protection</td>
<td>GOIs are hallmark</td>
</tr>
<tr>
<td class="label">Tau immunotherapy</td>
<td>Pathological tau in glia</td>
</tr>
<tr>
<td class="label">Myelin repair</td>
<td>White matter involvement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>ASOs targeting MAPT</td>
</tr>
<tr>
<td class="label">Haplotype modification</td>
<td>H1c risk haplotype</td>
</tr>
<tr>
<td class="label">Tau reduction</td>
<td>Antisense oligonucleotides</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Active Trials</td>
</tr>
<tr>
<td class="label">PSP</td>
<td>8</td>
</tr>
<tr>
<td class="label">CBD</td>
<td>3</td>
</tr>
<tr>
<td class="label">AGD</td>
<td>0</td>
</tr>
<tr>
<td class="label">GGT</td>
<td>0</td>
</tr>
<tr>
<td class="label">FTDP-17</td>
<td>0</td>
</tr>
<tr>
<td class="label">Total</td>
<td>11</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LMTM (Methylthioninium)</td>
<td>Tau aggregation</td>
</tr>
<tr>
<td class="label">ASN90</td>
<td>O-GlcNAcase</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR</td>
</tr>
<tr>
<td class="label">Coenzyme Q10</td>
<td>Mitochondrial function</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-MAPT</td>
<td>MAPT mRNA</td>
</tr>
<tr>
<td class="label">AAV-tau</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">CRISPR-based</td>
<td>MAPT gene</td>
</tr>
</table>

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms. While [Progressive Supranuclear Palsy (PSP](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT](/diseases/globular-glial-tauopathy), and [FTDP-17](/diseases/ftdp-17) share common pathological features centred on tau dysfunction, each disease presents unique therapeutic opportunities and challenges. This page provides a comprehensive comparison of therapeutic targets across these conditions, highlighting both shared pathways and disease-specific approaches.

Diseases Covered

Cross-Disease Mechanisms

Mermaid diagram (expand to render)

Shared Therapeutic Targets

Several therapeutic strategies target common mechanisms across all 4R-tauopathies. These represent the highest-priority opportunities for disease-modifying therapies.

1. Tau-Directed Therapies

Tau protein dysfunction is the central pathological feature across all 4R-tauopathies. The following tau-targeted approaches are under active investigation:

Tau Aggregation Inhibitors

Tau Immunotherapy

Active and passive immunization approaches target pathological tau species:

AADvac1 (Axon Neuroimmunology): Active vaccine targeting pathological tau; completed Phase I for AD, planned for 4R-tauopathies[@axon]
Semorinemab (Genentech): Anti-tau monoclonal antibody; failed in PSP, ongoing for CBD
Lu AF87908 (Lundbeck): Anti-tau antibody targeting 4R-tau; Phase I ongoing

Tau Kinase Inhibitors

The overactivation of tau kinases (GSK-3β, CDK5, JNK) promotes pathological phosphorylation. GSK-3β inhibitors have been explored extensively:

Lithium: Failed in PSP clinical trials due to tolerability issues
Valproic acid: Failed in PSP trials
Tideglusib: Non-selective GSK-3β inhibitor; failed in AD trials

2. Neuroinflammation Modulation

Chronic neuroinflammation drives progression across all 4R-tauopathies. Key targets include:

Microglial Modulation

NLRP3 Inflammasome Inhibition

MCC950: Potent NLRP3 inhibitor; preclinical promise in AD/PD, under exploration for PSP/CBD
Dapansutrile: Phase II in inflammatory conditions

Complement Inhibition

Eculizumab: C5 inhibitor; explored in ALS/FTD
Anti-C1q antibodies: Preclinical in tauopathy models

3. Autophagy and Proteostasis Enhancement

Tau clearance through autophagy-lysosome and ubiquitin-proteasome pathways is impaired across 4R-tauopathies:

Autophagy Inducers

4. Neuroprotective Agents

Several neuroprotective strategies show promise across multiple 4R-tauopathies:

Mitochondrial Protection

Coenzyme Q10: Variable results in PSP; ongoing investigations
Idebenone: Failed in Friedrich's ataxia, under exploration in PSP
Mitochondrial peptides (MMP): Phase II in PD

Synaptic Protection

Levetiracetam: Shows cognitive benefits in AD; potential for CBS/PSP
Ampa Receivers: Ampalon, perampanel: Under investigation

Disease-Specific Therapeutic Targets

Progressive Supranuclear Palsy (PSP)

PSP has the most robust therapeutic development pipeline among 4R-tauopathies:

Key ongoing trials:

NCT06065016: Tau PET imaging with [18F]-PI-2620 in PSP
NCT05903290: Coral calcium supplementation in PSP

Corticobasal Degeneration (CBD)

CBD therapeutic development lags behind PSP, though several approaches are emerging:

Argyrophilic Grain Disease (AGD)

AGD lacks disease-specific clinical trials due to diagnostic challenges during life:

Globular Glial Tauopathy (GGT)

GGT is the rarest 4R-tauopathy with no disease-specific clinical trials. Therapeutic approaches are based on shared mechanisms:

FTDP-17

FTDP-17 represents a genetic 4R-tauopathy with unique therapeutic considerations:

Clinical Trial Landscape Summary

Therapeutic Priority Ranking

Based on evidence strength and biological rationale, the following ranking applies across 4R-tauopathies:

Tau-directed immunotherapy — Highest priority, targeting core pathology

Autophagy enhancement — Addresses protein clearance

Neuroinflammation modulation — Modifies disease progression

Synaptic protection — Preserves cognitive/ motor function

Mitochondrial support — Cellular energy maintenance

[Tau Protein](/proteins/tau)
[4R-Tau Protein](/proteins/4r-tau)
[Tauopathy Mechanisms](/mechanisms/tauopathy)
[PSP Pathway](/mechanisms/psp-pathway)
[CBD Pathway](/mechanisms/cbd-pathway)
[Neuroinflammation in 4R-Tauopathies](/mechanisms/neuroinflammation-4r-tauopathies)
[CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
[CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan)
[Coenzyme Q10 for Neurodegeneration](/therapeutics/coq10-neurodegeneration)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Axon Neuroimmunology AADvac1 Phase I Results (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28753413/)

[Unknown, Semorinemab in PSP Phase II Trial (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34524733/)

[Wenger et al., Methylthioninium in PSP Phase II (n.d.)](https://doi.org/10.1002/alz.12090)

[Unknown, FTDP-17 MAPT Mutations Review (n.d.)](https://pubmed.ncbi.nlm.nih.gov/20372218/)

[Ahmed et al., GGT Pathology and Classification (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23400634/)

Unknown, Neuroimmune Response in 4R-Tauopathies: Cross-Disease Comparison (n.d.)

Unknown, Tau Filament Structures in 4R-Tauopathies (n.d.)

2025-2026 Clinical Trial Updates

Recently Completed and Active Trials

Recent clinical trial data has provided important insights into therapeutic development for 4R-tauopathies:

Tau Immunotherapy Updates

Small Molecule Updates

Gene Therapy and ASO Approaches

Biomarker Development (2025-2026)

Recent advances in biomarker development are improving clinical trial design:

Plasma p-tau217: now validated for detecting AD pathology in CBS cohorts; higher specificity than p-tau181
Neurofilament light chain (NfL): established as disease progression marker in both CBS and PSP
Tau PET ligands: 18F-PI-2620 shows specificity for 4R-tauopathies vs AD
CSF biomarker panels: Combined NfL + p-tau181 + Aβ42 achieves ~82% accuracy for CBS vs PSP differentiation

Emerging Therapeutic Targets

Several novel approaches have entered the pipeline:

Tau propagation blockers: Targeting extracellular tau uptake and cell-to-cell transmission

YAP/TAZ (Hippo pathway): Pro-survival signaling restoration in tauopathies

TREM2 modulators: Microglial function optimization

NLRP3 inflammasome inhibitors: MCC950 and analogs for neuroinflammation

Complement inhibitors: C1q and C3 targeting for synaptic protection

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — 0.73 · Target: C1Q/C3
[Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — 0.64 · Target: CSGA
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption](/hypothesis/h-8bd89d90) — 0.50 · Target: PHB2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — 0.52 · Target: TFEB

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Cross-Disease Therapeutic Targets in 4R-Tauopathies

Cross-Disease Therapeutic Targets in 4R-Tauopathies

Overview

Cross-Disease Therapeutic Targets in 4R-Tauopathies

Overview

Diseases Covered

Cross-Disease Mechanisms

Shared Therapeutic Targets

1. Tau-Directed Therapies

Tau Aggregation Inhibitors

Tau Immunotherapy

Tau Kinase Inhibitors

2. Neuroinflammation Modulation

Microglial Modulation

NLRP3 Inflammasome Inhibition

Complement Inhibition

3. Autophagy and Proteostasis Enhancement

Autophagy Inducers

4. Neuroprotective Agents

Mitochondrial Protection

Synaptic Protection

Disease-Specific Therapeutic Targets

Progressive Supranuclear Palsy (PSP)

Corticobasal Degeneration (CBD)

Argyrophilic Grain Disease (AGD)

Globular Glial Tauopathy (GGT)

FTDP-17

Clinical Trial Landscape Summary

Therapeutic Priority Ranking

Cross-Linking to Related Pages

See Also

External Links

References

2025-2026 Clinical Trial Updates

Recently Completed and Active Trials

Tau Immunotherapy Updates

Small Molecule Updates

Gene Therapy and ASO Approaches

Biomarker Development (2025-2026)

Emerging Therapeutic Targets

Related Hypotheses